Met Life Investment Management, LLC Arbutus Biopharma Corp Transaction History
Met Life Investment Management, LLC
- $16.6 Billion
- Q2 2024
A detailed history of Met Life Investment Management, LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Met Life Investment Management, LLC holds 81,711 shares of ABUS stock, worth $321,941. This represents 0.0% of its overall portfolio holdings.
Number of Shares
81,711
Previous 61,872
32.06%
Holding current value
$321,941
Previous $159,000
58.49%
% of portfolio
0.0%
Previous 0.0%
Shares
33 transactions
Others Institutions Holding ABUS
# of Institutions
138Shares Held
95.4MCall Options Held
3.44MPut Options Held
377K-
Morgan Stanley New York, NY21MShares$82.6 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY12.9MShares$50.7 Million30.08% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$45.5 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.57MShares$33.8 Million10.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.02MShares$27.7 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $591M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...